Emerging research suggest Retatrutide , a dual stimulator targeting both GLP-1 and GIP , may offer a notable development for weight loss . Initial clinical tests have shown considerable losses in abdominal tissue, possibly outperforming current weight-loss medications . Despite this, further study is necessary to thoroughly understand its lasting e